Related Experiment Video
Updated: Feb 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic
Adam G Sowalsky1,2, Huihui Ye3, Manoj Bhasin4
1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract:
Primary prostate cancer can have extensive microheterogeneity, but its contribution to the later emergence of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. In this study, we microdissected residual prostate cancer foci in radical prostatectomies from 18 men treated with neoadjuvant-intensive androgen deprivation therapy (leuprolide, abiraterone acetate, and prednisone) and analyzed them for resistance mechanisms. Transcriptome profiling showed reduced but persistent androgen receptor (AR) activity in residual tumors, with no increase in neuroendocrine differentiation. Proliferation correlated negatively with AR activity but positively with decreased RB1 expression, and whole-exome sequencing (WES) further showed enrichment for RB1 genomic loss. In 15 cases where 2 or 3 tumor foci were microdissected, WES confirmed a common clonal origin but identified multiple oncogenic alterations unique to each focus. These findings show that subclones with oncogenic alterations found in mCRPC are present in primary prostate cancer and are selected for by neoadjuvant-intense androgen deprivation therapy. In particular, this study indicates that subclonal RB1 loss may be more common than previously appreciated in intermediate- to high-risk primary prostate cancer and may be an early event, independent of neuroendocrine differentiation, in the development of mCRPC. Comprehensive molecular analyses of primary prostate cancer may detect aggressive subclones and possibly inform adjuvant strategies to prevent recurrence.Significance: Neoadjuvant androgen deprivation therapy for prostate cancer selects for tumor foci with subclonal genomic alterations, which may comprise the origin of metastatic castration-resistant prostate cancer. Cancer Res; 78(16); 4716-30. ©2018 AACR.
Insights
Primary prostate cancer harbors aggressive subclones that are selected by neoadjuvant androgen deprivation therapy. These subclones, particularly those with RB1 loss, may drive the development of metastatic castration-resistant prostate cancer.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Prostate cancer exhibits microheterogeneity, but its role in metastatic castration-resistant prostate cancer (mCRPC) development is not fully understood.
- Neoadjuvant androgen deprivation therapy (ADT) is a common treatment for prostate cancer, but its impact on subclonal evolution requires further investigation.
Purpose of the Study:
- To investigate the contribution of primary prostate cancer microheterogeneity to the emergence of mCRPC.
- To identify resistance mechanisms selected by neoadjuvant-intensive ADT in residual prostate cancer foci.
Main Methods:
- Microdissection of residual prostate cancer foci from radical prostatectomies of 18 patients treated with neoadjuvant ADT (leuprolide, abiraterone acetate, prednisone).
- Transcriptome profiling to assess AR activity and neuroendocrine differentiation.
- Whole-exome sequencing (WES) to identify genomic alterations, including RB1 loss and subclonal evolution.
Main Results:
- Residual tumors showed reduced but persistent androgen receptor (AR) activity without increased neuroendocrine differentiation.
- RB1 expression correlated negatively with proliferation, and WES revealed enrichment for RB1 genomic loss.
- WES confirmed common clonal origins but identified unique oncogenic alterations in distinct tumor foci, indicating subclonal heterogeneity.
Conclusions:
- Subclones with oncogenic alterations characteristic of mCRPC are present in primary prostate cancer and are selected by neoadjuvant ADT.
- Subclonal RB1 loss may be an early, frequent event in intermediate- to high-risk prostate cancer, preceding neuroendocrine differentiation and contributing to mCRPC.
- Comprehensive molecular analysis of primary tumors could identify aggressive subclones and guide adjuvant therapy strategies to prevent recurrence.
Related Concept Videos
Insufficient Sleep and Sleep Deprivation
Sleep deprivation is a more severe form of sleep loss...
Alterations in Respiration II
In Biot's breathing, the respiratory rate and depth are irregular, alternating between periods of deep gasping and apnea. Common causes...
Altered States of Awareness
The ingestion of substances like stimulants or hallucinogens leads to chemical alterations in the brain...
Sound Intensity
Diversity of Archaea I
Cell Diversity
Multicellular...

